Example: dental hygienist
KRYSTAL-1: ACTIVITY AND PRELIMINARY …
elcc-congress.org KRYSTAL-1: ACTIVITY AND PRELIMINARY PHARMACODYNAMIC (PD) ANALYSIS OF ADAGRASIB (MRTX849) IN PATIENTS (PTS) WITH ADVANCED NON–SMALL-CELL LUNG CANCER (NSCLC) HARBORING KRASG12C MUTATION Gregory J. Riely1, Sai-Hong Ignatius Ou2, Igor I. Rybkin3, Alexander I. Spira4, Kyriakos P. Papadopoulos5, Joshua …
Information
Domain:
Source:
Link to this page:
Documents from same domain
MRTX1719: A First -in-class MTA-cooperative PRMT5 ...
www.mirati.comMRTX1719 selectively binds the PRMT5 MTA complex which is elevated in . MTAP. del cancer cells and is therefore positioned to have an improved therapeutic index based on the concept of synthetic lethality MRTX1719 was identified as a development candidate which selectively binds the PRMT5 MTA complex. 1
KRYSTAL-1: Adagrasib (MRTX849) as Monotherapy or in ...
www.mirati.comSep 18, 2021 · Molecular status (BRAF V600E mutation, MSI-H or dMMR, EGFR amplification, TP53 mutation, PIK3CA mutation) includes patients with conclusively evaluable test results. Data as of 25 May 2021 for monotherapy (median follow-up: 8.9 months).
KRYSTAL-1: Updated Safety and Efficacy Data With ... - Mirati
www.mirati.comPresented at the 32nd EORTC-NCI-AACR Symposium, October 24- 25, 2020 • Grade 5 TRAEs included pneumonitis in a patient with recurrent pneumonitis (n=1) and cardiac failure (n=1) • 7.3% of TRAEs led to discontinuation